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ABSTRACT 
 Our knowledge of spinal cord injury repair is broadening with the developing 
technology for nerve regeneration and drug delivery.  In this paper we discuss the current 
capabilities for spinal cord repair as well as those that are in development.  We develop 
protocols for determining the thermal stability of chondroitinase ABCI and its ability to 
be implanted into a microtubule-hydrogel drug delivery vehicle as well as the release 
profile that results from this implantation.  After the use of sodium dodecyl 
electrophoresis, we determined that the disaccharide trehalose has the capacity to 
thermally stabilize our therapeutic enzyme in vitro.  We also determined that the 
microtubules are effective for sustaining the release of our enzyme while the hydrogel is 
effective for localizing its effects.  The deactivation profile was experimentally quantified 
to allow for complete diffusion of our enzyme over the course of a two-week 
implantation.  Our thermally stabilized enzyme and drug delivery system can be used for 
the purpose of facilitating nerve regeneration at the site of an injury. 
 
1. INTRODUCTION 
Spinal cord injury results in short-term and long-term loss of nerve control.  In 
order to overcome injuries that sever nerves in the spinal cord, we can deliver socialized 
proteins to the site of injury that facilitate the redevelopment of these nerves.  One such 
enzyme is chondroitinase ABCI (chABC).  My research with Hyun Jung Lee, under the 
advisement of Dr. Ravi Bellamkonda, will improve the thermal stability of the enzyme 
chABC and determine the loading efficiency of the microtubule drug delivery vehicles 
that will be used to localize the enzyme at the injury site. The drug delivery vehicles were 
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implanted in vivo with a topical model to observe the cellular responses after spinal cord 
injury and quantify the functionality of the released chABC.  The enzyme chABC was 
combined with brain-derived neurotrophic factor (BDNF) to facilitate the axonal 
recovery.  We utilized the deactivation profile of the gel scaffolds to deliver the 
appropriate quantity of enzyme at the lesion site.  We also attempted to produce longer 
microtubules by manipulating the protocol for their synthesis and holding the cooling 
process near the lipid melting point for longer durations. The quantification of the release 
profile facilitates the surgical implantation of our therapeutic drug delivery vehicle for the 
repair of spinal cord injury. 
 
2. LITERATURE REVIEW 
 The field of clinical spinal cord repair is still in its infancy; while its history is 
very brief, it is nonetheless dynamic in its onset.  This literature review is divided into 
two sections, the first focusing on overcoming the inhibitory molecules present at the site 
of injury and the second on focusing on the microtubule-hydrogel drug delivery pathway.  
In each, I provide a brief overview of the developments thus far followed by a statement 
of how the previous research will be built on in our lab. 
 
2.1 Inhibitory Molecules for Nerve Regeneration 
 Chondroitin sulphate proteoglycans (CSPGs) are axon growth inhibitory 
molecules present in and around scar tissue (Lin 1970).  After spinal cord injury, victims 
exhibit lower levels of sensory and motor function due to inhibitory molecules such as 
CSPGs that gather at the lesion site and prevent nerve regeneration.  For this reason, there 
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has been a concerted effort by field researchers Anjana Jain, Young-Tae Kim, Robert 
McKeon and Ravi Bellamkonda to remove all CSPGs from a lesion site, effectively 
promoting nerve and functional regrowth.  In July 2005, there existed no clinical strategy 
to promote regeneration in the injured spinal cord (Jain 497).  Anjana Jain developed a 
clinical strategy in the form of microtubules in a BDNF-embedded agarose scaffold that 
conformally filled a spinal cord defect.   
The agarose scaffold is ideal for neuronal applications because of its 
biocompatibility in vivo, its support of cell migration, its ability to be embedded with 
sustained release vehicles such as microtubules and its ability to bind protein to its 
backbone for spatial control (Jain 498).  The mechanical properties of agarose can also be 
manipulated for optimal axonal outgrowth (Meilander 142).  Jain embedded the agarose 
delivery vehicles with BDNF in an attempt to prove this method was capable of reducing 
the reactivity of the astrocytes and production of CSPGs that was responsible for 
hindering nerve regeneration.  
After staining cross sections of the spinal cord injury with antibodies GFAP and 
CS-56 to identify reactive astrocytes and CSPG deposition, respectively, Jain found that 
the samples treated with BDNF exhibited significantly lower fluorescent levels of both, 
indicating BDNF's ability to significantly prevent the production of the inhibitory 
molecules.  This breakthrough encouraged researchers to begin investigating the optimal 
ways in which the BDNF scaffolds could provide a supportive substrate for neurite 
expansion (Jain 502).  The problem with this treatment lies in the fact that BDNF could 
only prevent the production of CSPGs, but it could not do anything to remove the CSPGs 
that were already present at the site of injury.  Realistically, there is a significant duration 
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of time that elapses after spinal cord injury when the body delivers CSPGs to the lesion 
site before treatment is performed.  In order to remove the CSPGs that are already 
gathered at the lesion site, there is a need for further research into not only CSPG 
prevention, but also CSPG removal. 
The removal of these molecules is facilitated with the enzyme chABC.  ChABC 
effectively cleaves the chondroitin sulphate glycosaminoglycan (GAG) chains 
responsible for growth inhibition.  This enzyme promotes both axon regeneration and 
plasticity, but the problem lies in its ability to be used in vivo (Moreno-Flores 56).  The 
enzyme is not biocompatible and denatures at body temperature, something that must be 
overcome before it is implanted at a site of injury.   
To thermally stabilize the chABC, trehalose will be tested to see if it increases the 
lifetime of enzymatic activity at 37 degrees Celsius (Sakai 380).   Trehalose is effective 
in enhancing the transgene expression mediated by DNA complexes (Tseng 1298).  This 
characteristic is a direct result of its ability as a disaccharide to stabilize the structure of 
proteins.  Trehalose stabilizes proteins while reducing immunosuppression and having 
minimal effects on the machinery of protein synthesis (Adamo 531).  A study into plant 
physiology proved that the accumulation of trehalose in anhydrobiotic organisms allows 
them to survive severe environmental stress (Zentella 1473).  The deactivation curve will 
be determined by measuring the enzymatic activity of chABC over a given number of 
days (Sakai 381).   
Once the stabilization has been accomplished, we must develop an enzyme 
delivery pathway that allows the enzyme to be deposited at the site of injury over a long 
period of time.  As of now, injection into test rats suggested the persistence of active 
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chABC for at least 10 days after injection (Lin 1990).  The fact that chABC can 
significantly increase the critical length of nerve gap repair is motivation enough to try 
and harness its potential in vivo (Hattori 466). 
 
2.2 Microtubule-Hydrogel Efficacy 
Materials Science and Engineering researchers such as T.M. Allen, G. 
Gregoriadis, R. Santangelo, T.T. Hsu, J.K. Sherwood and M.V. Sefton began developing 
lipid-based systems to release therapeutic agents in the late 1980s.  These systems include 
liposomes, cochleates, polymer-based systems such as ethylene-vinyl acetate copolymer 
and polylactides (Meilander 141).  These systems are effective for drug delivery; 
however, they involve exposing the enzyme to organic solvents, and thus present the 
possibility of denaturing the protein and removing its ability to perform in vivo.  To 
overcome this limitation, Nancy Meilander, Xiaojun Yu, Nicholas Ziats and Ravi 
Bellamkonda helped develop a microtubule-hydrogel system that utilized lipid 
microtubules embedded in agarose hydrogels. 
These lipid microtubules were initially described by Yager and Schoen in 1984 as 
hollow and open-ended tubules with a lumen diameter of approximately 0.5 micrometers 
and walls formed of lipid bilayers (Schnur 1670).  Meilander's group utilized these 
microtubules to provide slow release of the loading agent along with the hydrogel to 
localize the microtubules at the desired site and prevent their dispersion (142). 
There are several different types of biocompatible and versatile lipid-based 
microtubule carriers for different therapeutic proteins and enzymes (Rawat 270). 
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Past research into local drug delivery has proven that d-alpha-Tocopheryl polyethylene 
glycol 1000 succinate is a novel additive to the poly(l-lactide) (PLLA) films (Dong 167).  
This addition proved to enhance facilitation of the release of the loading agent in vivo.  
Microtubules loaded with enzyme prove to be novel carriers for internal drug delivery.  
The size and concentration values of the loaded microtubules are factors that affect the 
long-term release profile of the enzyme (Wang 389).   
 Meilander studied the effect of protein molecular weight and found that it 
inversely affected the release rate.  Further, she observed the effect of a higher initial 
protein concentration and observed that it increased the mass but not the percentage of 
the initially loaded protein released daily (141).  These results still leave researchers with 
the task of utilizing these microtubules loaded with therapeutic agent to facilitate nerve 
regeneration.  This healing process can be accomplished by combining the microtubule-
hydrogel system with a porous scaffold that propagates and directionalizes nerve growth. 
 The purpose of porous scaffolds is to mimic the fibrous architecture of type I 
collagen, where nerve growth is optimal (Chen 2066).  Some methods utilize a phase 
separation technique that we have not tried in the lab.  This method allows the scientist to 
manipulate spherical pore size, interfiber distance, and fiber diameter while promoting 
cell seeding.  However, we will utilize salt leaching, where the interconnectivity between 
pores is low and difficult to control and the fiber diameters are far greater than the typical 
fibers of the extracellular matrix (Chen 2067).  The most simple and practical, this crude 
method of scaffold production will suffice to obtain the data sets for my research.   
 Research into cell proliferation within the PLLA scaffold has been done in the 
form of incubating a specimen over the course of 1 and 2 weeks (Ren 507).  The 
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researchers also observed the cell morphology on the scaffold-cultured cells using SEM, 
which gave them insight into how effective cell growth is inside of a porous scaffold.  
These scientists observed cells attached to the pore surface and conglomeration of cells in 
some areas of the scaffold.  The cells were concentrated in the gaps of the scaffolds, 
giving incentive to do away with these gaps and focus on the creation of a more 
homogenous porous polymer.  A homogenous polymer will form microfibrilar structures 
within the pore walls of the PLLA foam that may act as additional soft anchorage sites 
for cells (Prabaharan 427).   
 
3. MATERIALS AND METHODS 
3.1 Analysis of Enzymatic functionality  
The enzymatic functionality of chABC was examined using a molecular weight 
separation technique, SDS-PAGE.  The substrate protein that was incubated with the 
chABC was decorin, with a known molecular weight of approximately 100 kDa.  When 
digested by chABC, the decorin only exhibited its core weight of approximately 40 kDa.  
This discrepancy allowed for the determination of chABC's activity.  The samples 
affected with chABC were cured with cross-linking sulfur molecules to produce a high 
net negative charge.  These samples were then be loaded into an electrophoresis gel and 
run through a voltage gradient to allow for separation based on molecular weight.  The 
results of the experiment allowed for the quantification of each sample's molecular 
weight and served as an indication of chABC's enzymatic functionality.   
The procedure involved diluting protein samples 1:1 with Tris-SDS sample buffer 
containing 5% mercaptoethanol to denature the protein and incubating at 95 degrees 
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Celsius for four minutes.  The gel electrode was placed into the electrophoresis chamber 
filled with Tris running buffer.  Twenty microliters of each sample were loaded into each 
lane and electrophoresed at 200 Volts for one hour.  Diluted chABC in PBS with and 
without trehalose was prepared to determine the difference in enzymatic activity with the 
addition of trehalose.  The absorbance of fresh chABC with chondroitin sulfate C was 
considered the standard at 100% activity.  This data will allow for the production of the 
deactivation curve. 
 
3.2 Synthesis of lipid microtubules and loading agent 
 Hollow, open-ended lipid microtubules were synthesized using 1,2-bis-(triscosa-
10-12-diynoyl)-sn-glycero-3-phosphocholine.  The lipid was dissolved in 70% ethanol 
and cooled from 55 to 21 degrees Celsius, heated to 33 degrees Celsius and cooled again 
to 20 degrees Celsius for 48 hours.  The microtubules self-assembled during this cooling 
procedure and after 2 weeks of incubation at room temperature, 50 mM trehalose were 
mixed and incubated overnight.  After centrifuging and drying overnight, the 
microtubules were embedded with the loading agent based on the loading efficiency.  To 
measure the functionality of the fresh microtubules, the microtubule/trehalose mixture, 
without pre-incubation at 37 degrees Celsius, was combined with decorin.  The samples 
were centrifuged after 6 hours of incubation and the supernatant was analyzed with 
dimethylmethylene blue. 
 The protocol for synthesizing the microtubules was manipulated in an attempt to 
produce larger microtubules.  The cooling process was lengthened at certain points and 
the resultant microtubules were observed to determine average length.  Larger 
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microtubules would facilitate the capability for more of the therapeutic enzyme to be 
loaded and ultimately released at the lesion site. 
 
3.3 Kinetic Analysis of chABC: Deactivation curve 
 In order to measure the kinetic activity of the enzyme, a protocol involving 
dimethylmethylene blue (DMMB) was used.  A sample of diluted chABC mixed with 
trehalose was incubated at 37 degrees Celsius.  For two weeks, a sample of the incubated 
solution was extracted every other day and mixed with a 200 µg/ml decorin solution.  
After incubation, the DMMB was added to the sample and the absorbance was recorded 
at 520 nm.  As a control, the absorbance of the enzyme without decorin was recorded and 
subtracted from the other absorbance reading.  This procedure was repeated with chABC 
and no trehalose, whose absorbance was compared with the trehalose-stabilized enzyme.  
The deactivation curve was calculated by determining the percentage of the destabilized 
enzyme's absorbance in relation to the trehalose-stabilized enzyme. 
 
3.4 Release profile of chABC from gel scaffolds 
 SeaPlaque was dissolved in PBS to produce an agarose concentration of 1.2%.  
After cooling the solution to 37 degrees Celsius, the gel was mixed with the volume of 
microtubules embedded with chABC/trehalose and put in a 48-well plate.  The final 
concentration summed to 0.6%.  The mixture gelled and incubated for two weeks.  The 
supernatant was taken during incubation to determine the amount of released protein.  
Every other day, the PBS was sampled and replaced.  The supernatant was mixed with 
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decorin and incubated at 37 degrees Celsius, at which point the sample was analyzed with 
the dimethylmethylene blue to quantify the release profile of the gel scaffold. 
 
3.5 Fabrication of gel scaffolds and topical delivery 
 The microtubules, loaded with chABC/trehalose, was mixed with 1.2% filtered 
and sterilized SeaPlaque to obtain a final concentration of 0.6% gel.  After gelling, a 15 
microliter volume of the gel scaffold was implanted into each animal.  The gelled 
scaffold of the microtubule-hydrogel complex loaded with the thermally-stablized 
enzyme, was delivered into a dorsal hemisection animal model.  A two-millimeter cubed 
scaffold was implanted on top of the lesion site and 0.7% SeaKem was used to cover the 
scaffold. 
 
3.6 Immunohistology and Quantitative Analysis 
 To determine the enzymatic functionality of the chABC, the cross sections of the 
lesion site was stained with 3B3, 2B6, GFAP and CS56.  Positive areas of astrocytes, 
digested CSPGs and intact CSPGs were thereby observed.  Immunostained images were 
analyzed with custom-built software in MATLAB.  The software generated line profiles 
radial to the defined interface and produced an output of the intensity of the stained signal 
along the profile.  This output could be used to determine the relative intensity as a 
function of distance from the lesion interface. 
 
3.7 Diffusion Profile 
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 In order to visualize the diffusion profile of the microtubules, the loaded enzyme 
had to be conjugated with rhodamine.  The chABC and rhodamine were dissolved in 
deionized (DI) water and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(EDC), which acts as a coupling agent for the conjugation.  The reaction was allowed 24 
hours at room temperature without light and then dialyzed against DI water for two 
hours.  The dialysis removes the unused reactants from the solution and leaves the 
conjugated rhodamine-chABC complex. 
 The diffusion profile of the microtubules was thereby qualitatively viewed by way 
of the rhodamine staining.  The stained enzyme was loaded into the microtubules and 
allowed to diffuse through the surrounding gel medium.  Pictures were taken on the hour 
for three hours to determine the efficiency of the microtubule diffusion. 
 
4. RESULTS 
4.1 Enzymatic functionality of chABC 
 The enzymatic activity of chABC was tested using SDS-PAGE.  This protein 
assay allowed for the comparison of the decorin substrate when exposed to chABC in its 
active and inactive states.  The enzymatic functionality of chABC is shown in Figure 1.   
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Figure 1.  Enzymatic functionality test of chABC.  The lanes represent (1) the ladder, (2) intact decorin (3) 
decorin reacted with pre-incubated chABC, and (4) decorin reacted with fresh chABC. 
 
In Lane 2, a sample of intact decorin was electrophoresed.  Lane 3 exhibits the 
electrophoresis of decorin reacted with chABC pre-incubated at 37 ºC for 24 hours.  Lane 
4 exhibits the electrophoresis of chABC incubated for 4 hours at 37 ºC.  The substrate 
protein, decorin, was reacted with fresh chABC for 4 hours at 37 ºC, producing a clear 
band in Lane 4 at 45 kDa, indicating digestion of the substrate.  Not surprisingly, Lanes 2 
and 3 are very comparable, displaying that the pre-incubated chABC produced the same 
results as the intact decorin, indicative of chABC’s loss of enzymatic functionality when 
exposed to body temperature. 
 
4.2 Thermal stability of chABC with trehalose 
 Trehalose at 20 mM, 50 mM, 100 mM, 250 mM, 500 mM and 1 M was reacted 
with chABC to examine the ability of the sugar-enzyme complex to retain its function 
when exposed to body temperature.  The trehalose-chABC samples were pre-incubated at 
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37 ºC for 2 weeks and allowed to react with decorin at 37 ºC for 4 hours.  The results of 
the electrophoresed samples are displayed in Figure 2. 
 
Figure 2. Enzymatic functionality test with various concentration of trehalose after incubation at 37 ºC for 
2 weeks.  The lanes represent (1) decorin with fresh chABC, (2) 20 mM, (3) 50 mM, (4) 100 mM, (5) 250 
mM, (6) 500 mM, (7) 1 M trehalose incubated with decorin, and (8) the ladder. 
 
After running the samples through the gel, there is clear indication that decorin was only 
digested in Lanes 1, 6, and 7.  This is telling of the concentration of trehalose needed to 
fully stabilize the enzyme and allow it to retain its functional ability through a 2-week 
incubation period.  Only chABC incubated with 500 mM and 1 M trehalose could 
prevent the denaturing of chABC at body temperature.   
 
4.3 Deactivation Curve 
 The enzymatic activity of chABC was analyzed every two to three days by 
determining the percent of decorin digested.  Figure 7 shows the deactivation profile of 
chABC both with and without trehalose. 
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Figure 7. Deactivation profile of chABC enzymatic activity by DMMB assay.  With the exception of day 
1, all paired T-tests between the control (chABC without trehalose) and chABC with trehalose produced a 
P-value less than 0.05, indicating the significance of trehalose on protein stabilization. 
 
 Comparing the two curves, it is evident that trehalose has a significant impact on 
the deactivation curve of the enzyme.  It took 14 days for the chABC without trehalose to 
lose all of its enzymatic activity.  The time until the enzyme-trehalose complex reaches 
complete deactivation is currently unknown. 
 
4.4 Microtubule Synthesis 
 After lengthening the cooling process used in microtubule synthesis, the resultant 
microtubules were examined at 10x magnification and imported to an image analysis 
software package.  Each microtubule was measured and the average length was 
calculated.  The microtubules did not exhibit an average length any greater than those 
produced from the original protocol.  Figure 3 displays a histogram of the microtubule 
population for both the original procedure and the new extended time procedure. 
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Figure 3. Histogram of microtubule population for both original and new protocol. (a) Histogram of the 
lengths of microtubule produced from the original protocol.  The majority of microtubules were between 30 
and 40 microns long. (b) Histogram of the lengths of microtubules produced from the extended time 
protocol. The majority of microtubules produced were also between 30 and 40 microns long. 
 
 It is evident from comparing these charts that the new protocol did not 
significantly increase the length of the microtubules.  The distribution of lengths is very 
similar for both protocols. 
 
4.5 Lipid microtubules as a vehicle for controlled delivery 
 The lipid microtubules were loaded with the thermally-stabilized chABC to 
examine its ability as a carrier for sustained delivery.  The chABC released from the 
microtubules was combined with decorin and tested using SDS-PAGE.  The resultant 
electrophoresis produced bands at 45 kDa.  The functionality test of the chABC released 
from the microtubules is displayed in Figure 4.   
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Figure 4.  Functionality test of chABC released from microtubules.  The lanes represent (1) intact decorin, 
(2) fresh chABC and decorin, (3)(4)(5) fresh microtubules and decorin, and (6) the ladder. 
 
 The functionality test shows that the chABC released from the microtubules was 
still in its active form, since its substrate produced bands that indicate its digestion.  This 
is a promising result since it shows that the drug delivery system does not affect the 
potency of the enzyme. 
 This functionality test was used in conjunction with a control DMMB assay.  In 
the control, chABC-trehalose diffused from microtubules was compared with penicillin-
trehalose diffused from microtubules, which produced a deactivation curve as follows: 
 
Figure 5. Control deactivation curve for chABC against penicillin.  It is evident that the enzymatic ability 
of the trehalose with chABC-loaded microtubules is far more dramatic than that of trehalose with 
penicillin-loaded microtubules. 
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The hydrogel-microtubule delivery system was also implanted into a test rat to 
validate its applicability in vivo.  The results from the procedure proved biocompatibility 
of the scaffold; a schematic of the delivery model is displayed in Figure 6. 
 
Figure 6. Schematic of the modeled injury with the microtubule-hydrogel system of enzyme delivery.  The 
agarose gel scaffold is implanted on top of the lesion and coated with the stiffer agarose to prevent 
migration of the scaffold. 
 
4.6 Immunohistology and Quantitative Analysis 
 The cross sections immunostained with the antibodies CS-56 and GFAP 
recognized the intensity of CSPGs and reactive astrocytes, respectively.  The 
immunostained samples were photographed for image analysis and used as the input for 
custom MATLAB software that utilizes line profiles to relate relative intensity to distance 
from the lesion site interface.  Figure 8 displays the initial step for the image analysis in 
which a box is sampled at the lesion site interface. 
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Figure 8. Immunostaining of GFAP for reactive astrocytes.  The box is expanded here to display the 
analysis to be performed by the MATLAB code.   
 
The biological remnants of CSPGs and reactive astrocytes were shown to exhibit high 
intensity at the lesion interface, which exponentially decreased as a function of distance 
from the interface. 
 
4.7 Rhodamine-conjugated Diffusion Profile 
 The microtubules were allowed to diffuse their loaded enzyme stained with 
rhodamine and pictures were taken every hour.  The results are below: 
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Figure 9. Diffusion profile of the rhodamine-stained enzyme released from the microtubules.  (a) Diffusion 
profile after one hour. (b) Diffusion profile after two hours. (c) Diffusion profile after three hours.  
 
 These results make it difficult to see a significant difference between the hours of 
diffusion.  However, it is easy to view the difference in intensity at the top of the 
diffusion profile between hours one and two.  Although its intensity is more distributed 
throughout, the profile for the third hour spans the entire length of the medium, indicative 
of the diffusion effect for the rhodamine-stained enzyme.   
 
5. ANALYSIS 
5.1 Enzymatic functionality and kinetic analysis of chABC 
 The functionality of chABC is exhibited in the fact that the sample of decorin 
combined with the pre-incubated chABC in Lane 3 produced bands similar to the intact 
decorin in Lane 2.  The electrophoresis indicates that the decorin was not digested by the 
pre-incubated chABC, inferring chABC lost its enzymatic ability during its exposure to 
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the 37 ºC incubation.  This lack of biocompatibility needs to be compensated for before 
the enzyme is used in vivo. 
 
5.2 Thermal stability of chABC with trehalose 
 Even after 2 weeks of pre-incubation at 37 ºC, chABC combined with 500 mM or 
1 M trehalose produced bands of digested decorin.  The incubations with 20 mM, 50 mM, 
100 mM and 250 mM trehalose failed to produce electrophoresis bands around the 45 
kDa characteristic of digested decorin.  Therefore, if the enzyme is to be used in vivo, it 
must be incubated with a concentration of the stabilizing protein that is higher than 250 
mM.  The results for Lanes 6 and 7, 500 mM and 1 M trehalose, are strikingly similar, 
telling that increasing the trehalose concentration above 500 mM threshold will have 
minimal effects on chABC’s enzymatic ability. 
 
5.3 Microtubule Synthesis 
 Increasing the cooling time in an attempt to produce longer microtubules 
produced minimal results that were actually opposite of what was expected.  The majority 
of the microtubules were still between 30 and 40 microns, but the fraction of 
microtubules between 20 and 30 microns increased while the fraction of those between 
40 and 50 microns actually decreased.  The new protocol that called for a slower cooling 
process did not result in longer microtubules.  We will therefore not consider it in the 
experimental method for microtubule synthesis. 
 
5.4 Lipid microtubules as a system for controlled delivery 
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 The diffused chABC reacted with decorin and produced bands at 45 kDa, making 
it known that chABC does not lose its enymatic activity even when diffused from the 
lipid microtubules and hydrogel.  When diffused from a nanoparticle, chABC loses its 
enzymatic ability, making these microtubules a technological advancement in topical 
drug delivery for the enzyme.  This loss of enzymatic ability is due to the toxic process 
that must be used to synthesize the nanoparticles.  These results allow us to consider the 
sustained delivery system as a safe and effective way to localize the enzyme in vivo.   
 The topical delivery model on the test rat showed the functionality of the 
microtubule-hydrogel system.  The stiffer agarose that covered the gel scaffold 
effectively stabilized the system and was fortunately accepted by the rat’s anatomy.  
These clinical results are the initial steps to performing this type of operation on human 
patients. 
 
5.5 Deactivation Curve 
 Starting at day 2, the paired T-test between the deactivation profile of chABC and 
chABC with trehalose produced a P-value of 0.01.  This shows that the stabilizing effect 
of trehalose significantly increases the enzymatic activity of the enzyme.  The 14 days 
that it took for the naked enzyme to lose its enzymatic ability is rivaled by the 80% 
digested decorin that the stabilized enzyme was able to maintain after the same duration.  
These results are promising for the in vivo maintenance of chABC. 
 
5.6 Immunohistology and Quantitative Analysis 
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 The aggregation of CSPGs and reactive astrocytes at the lesion interface tells us 
where the BDNF scaffold with chABC-loaded microtubules needs to be localized.  In 
order to achieve maximum results, the microtubule-hydrogel system need only be 
implanted above the lesion site to deliver its therapeutic at the interface, where it will 
resist the gathering of the CSPGs present in the immunohistology analysis. 
 
5.7 Rhodamine-chABC Conjugated Diffusion Profile 
 The rhodamine-stained enzyme indicates the even distribution of the chABC 
throughout the medium.  This is indicative of the fact that the enzyme will spread 




 The problem of biocompatibility has been overcome with the use of trehalose as 
the protein stabilizer.  This sugar shows promise in making chABC immune to the 
denaturation that occurs at 37 ºC.  The enzyme can therefore be used in vivo for the 
removal of CSPGs from the site of injury, making the only remaining problem that of 
sustained delivery to the lesion site. 
 The microtubule-agarose partnership allowed for the loading of the enzyme as 
well as its active-state diffusion.  The resulting release profile can be manipulated by 
either changing the size of the microtubules or the concentration of the loading agent.  
Since microtubule size was unsuccessfully manipulated, we should rely on enzyme 
concentration to produce the desired enzyme immersion at the lesion interface.  Pending 
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on further research into the ideal enzyme quantity for the treatment of spinal cord injury, 
this concentration can be considered variable.   
 In order to prove the adaptability of the carrier system in vivo, the enzyme-loaded 
microtubules suspended in the gel scaffold will need to be implanted by way of the 
topical delivery model.  If this can be reproduced consistently, the biocompatibility of the 
system will be validated clinically.   
 As a result of the analyses, we have determined that the thermal stability of 
chABC when treated with the stabilizing trehalose is enhanced when compared to the 
quickly-denaturing enzyme without trehalose.  This overcomes the initial critical 
limitation of the clinical treatment for spinal cord injury.  Further, the steady release of 
the enzyme from the microtubule-hydrogel partnership was demonstrated as a possibility 
and can be sustained over a two-week period with minimal invasiveness to the patient. 
 The overall biocompatibility of the drug delivery system will be marketable to 
medical distributors and the general public upon approval from the necessary government 
agencies. With this system of therapy, the treatment of spinal cord injury will be 
minimally invasive, requiring only one operation on the patient.  The sustained delivery 
of chABC combined with the BDNF-embedded scaffold will allow for the digestion of 
gathered CSPGs and the prevention of others from aggregating.  By clearing the lesion 
site of these fatty acid chains, the treatment will facilitate the redevelopment and 
maturation of axons into the extracellular space. 
 The potential of such a technology is groundbreaking for the field of spinal cord 
injuries.  If successfully integrated into hospitals as the primary treatment for nerve 
damage, the partnership between chABC and BDNF will facilitate an ample environment 
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for nerves to develop.  This environment will need to be further analyzed to optimize this 
development, something that will prove to be the next frontier. 
 Further research is needed for a predictable manipulation of nerve regrowth.  
Engineers will need to be able to localize growth factors that will encourage nerves to 
develop once the enzyme has performed its task of clearing the site of inhibitory 
molecules.  The microtubule-agarose system will serve well to create an environment that 
has the potential to promote nerve regeneration.  However, to guarantee the nerves grow 
in the right direction and through the right space will require a nerve-friendly scaffold.  A 
scaffold will change the mere potential for regrowth into a surety for regrowth with the 
proper orientation and destination.  Ideally, this scaffold will be embedded with the 
growth factors necessary to initiate growth from the surrounding nerves and to reconnect 
the nerve ends for functional recovery of the axon potential.  The combination of a 
biocompatible scaffold that orients the direction of nerve growth with the microtubule-
agarose drug delivery vehicle will allow modern medicine to bypass the permanent 
sensory and motor loss previously associated with spinal cord injury.  
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